About Us
Science Driven.
Therapeutically Focused.
Unparalleled Metabolic Experience.
About Us

Connecting clients, partners and patients to advance clinical research and the development of breakthrough treatments for metabolic disease.

our focus

Our Focus - NAFLD/NASH, Diabetes and Obesity

our services

ProSciento Services - CRD, CRU, CRO and CRI

ProSciento's portfolio of global services, exclusively focused on metabolic diseases, provides flexible solutions that meet the specific needs of clients from large pharma to virtual and small biotechnology companies.

Our Values

ProSciento is proud to be driven by strong values. We take tremendous pride in the impact our team has made in science, for patients and in our community.

Read More »

Making a Difference.

drugs & devices

ProSciento’s executive leadership is internationally recognized for their contributions to the field of metabolic drug development, including program strategy, clinical trial conduct, regulatory submissions, and post-marketing research across all phases of the product development cycle.

Marcus Hompesch

Marcus Hompesch, M.D.

Chief Executive Officer and Chairman of the Board

Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board of ProSciento and has led the company since its inception in 2003. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally.

Prior to leading ProSciento, Dr. Hompesch was Chief Operating Officer of Profil Institut für Stoffwechselforschung GmbH and, before that, was founder and Chief Executive Officer of the medical technology company Med.IQ. He is an author of more than 100 publications, including peer-reviewed journals and editorials and is a regular peer reviewer for scientific journals relevant to metabolic diseases. He is also an editor and co-author of the textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

As a licensed physician in Europe he received his M.D. from the University of Düsseldorf, Germany, and following medical school trained in internal medicine and diabetology at the Klinikum Wuppertal Medical Center. He also was a scientific associate at the Department of Medical Informatics, Bio-Statistics and Epidemiology at the Ruhr University Bochum, Germany.

Linda Morrow

Linda Morrow, M.D.

Chief Medical Officer

Dr. Linda Morrow is Chief Medical Officer at ProSciento, Inc. Her career in metabolism-focused clinical R&D, spanning more than 25 years, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally today.

Prior to her role as Chief Medical Officer, Dr. Morrow was Vice President and Chief Operating Officer for ProSciento with oversight of the clinical operations, project management and subject recruitment teams for global multi-site CRO studies and ProSciento’s state-of-the-art early phase facility in San Diego. During her role in this leadership position, ProSciento gained an industry-wide reputation as the leading organization for early phase diabetes research and one of only a few CROs with the experience and expertise in designing and conducting NASH first-in-human studies.

Read More »
Markus Hoffman

Markus Hofmann

Chief Financial Officer

Markus Hofmann is ProSciento’s Chief Financial Officer overseeing the company’s accounting and financial operations. Mr. Hofmann has had a leadership role in ProSciento’s finance department since 2013 when he joined the company as Corporate Controller and Vice President of Financial Services. Prior to this, Mr. Hofmann was an executive level financial consultant for ProSciento and Volcano Corporation, a public medical device company, specializing in streamlining accounting processes; identifying key metrics to track a company’s financial performance; and systemizing stock and similar administration plans. Before his role as a consultant, Mr. Hofmann was the Controller at Verari Systems, Inc., a private technology company, and Genetronics, Inc., a public medical device company. Mr. Hofmann has a Bachelor’s degree in Business from Coleman College and is a Certified Public Accountant (CPA), Certified Management Accountant (CMA), and Certified in Financial Management (CFM).

Board of Directors
Building scientific knowledge.
Driving innovation.
Achieving success.

ProSciento's Board members have been at the forefront of metabolic research and drug development, both in industry and academia, and have held leadership positions at more than 25 life science companies.

Marcus Hompesch, M.D.

Chief Executive Officer and Chairman of the Board

Kelvin Logan, Ph.D.

Industry consultant and former President of Europe, Asia and Latin America at INC Research

John Amatruda, M.D.

Pharmaceutical Research Executive and Former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories

Linda Morrow, M.D.

Chief Medical Officer

Dan Bradbury

Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO

Jerrold Olefsky, M.D.

Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine


Stay Connected

Would you like to receive updates from ProSciento?

I'm interested in receiving: